Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04915131 · ClinicalTrials.gov registry record · NA

A Clinical Study for Validating the Equivalence of Bloomlife MFM-Pro to Clinical Standard-of-care for Performing Antepartum Fetal Monitoring

A NA study, sponsored by Bloom Technologies.

Completed
Registry status
NA
Development phase
121
Enrollment target

NCT04915131 is a NA study that has completed, run by Bloom Technologies. The registered enrollment target is 121 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04915131, a NA study, has completed, sponsored by Bloom Technologies.

COMPLETED
Registry status
NA
Development phase
121 participants
Enrollment target

Study Summary

Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy, starting from 32 weeks of gestation. The purpose of this study is to validate that the Bloomlife MFM-Pro is equivalent to clinical standard-of-care for fetal heart rate and maternal heart rate when performing antepartum fetal monitoring.

Interventions

  • DEVICE Bloomlife MFM-Pro

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2021-04-06
Est. Completion 2022-05-05
Phase NA

Sponsor

Bloom Technologies

2 total trials

What the Registry Record Tells You About NCT04915131

The ClinicalTrials.gov registry entry for NCT04915131 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bloom Technologies, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Bloomlife MFM-Pro is the first listed.

NCT04915131 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04915131 about?

NCT04915131 is a clinical study titled "A Clinical Study for Validating the Equivalence of Bloomlife MFM-Pro to Clinical Standard-of-care for Performing Antepartum Fetal Monitoring". Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy, starting from 32 weeks of gestation. The purpose of this study is to validate that the Bloomlife MFM-Pro is equivalent to ...

What is the current status of trial NCT04915131?

This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2021-04-06. Estimated completion is 2022-05-05.

What interventions are being tested in trial NCT04915131?

The interventions under investigation include: Bloomlife MFM-Pro (DEVICE).

Who is sponsoring clinical trial NCT04915131?

This trial is sponsored by Bloom Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.